U.S. Markets closed

Prana Biotechnology Limited (PRAN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.56+0.07 (+2.81%)
At close: 4:00PM EDT
People also watch
CYCCOPXAIDRAGALEIMUC
  • P
    Pivalde
    Pivalde
    Somebody shaking the tree. Down 12 % during the last hour.
  • F
    Frances
    Frances
    Closed at near low of day but volume remains fairly low @77,299 shares as compared with daily average 91,704 shares. No post-market trading so far. Prana rumors usually go the other way - temporarily up instead of this dip.
  • F
    Frances
    Frances
    52-week change - (minus)54.17%

    from finance.yahoo.com statistics link above
  • F
    Frances
    Frances

    https://finance.yahoo.com/quote/PBT.AX/community?p=PBT.AX

    Another exciting(?) day/year on PBT.AX
    52-week range...................$0.042 - 0.120
    Thurs Aug 17 range........... 0.053 - 0.055

  • j
    james
    james
    Down big after hours!!!
  • A
    Ashby
    Ashby

    This is where I find the top NASDAQ & NYSE Trade Ideas ---> www.T0pm@rketgainers.c0m

  • F
    Frances
    Frances
    Beware those who ignore statistics but claim superiority with nothing to sell
    PRAN........$20.8M market capitalization
    LLY............$87.415B
    PFE...........197.83B
    JNJ............335.181B
    MRK..........176.35B
  • S
    Scott
    Scott

    Anyone familiar with this research? Binghampton Univ. just announced a Parkinson's drug:

    https://medicalxpress.com/news/2017-07-drug-limit-parkinson-disease.html

    New drug may treat and limit progression of Parkinson's disease
    Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.
    medicalxpress.com
  • P
    Pivalde
    Pivalde
    Journal Article
    Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline

    Scott Ayton, Amir Fazlollahi, Pierrick Bourgeat, Parnesh Raniga, Amanda Ng ...
    Published: 26 July 2017
    Abstract
    See Derry and Kent (doi:10.1093/awx167) for a scientific commentary on this article.
    The large variance in cognitive deterioration in subjects who test positive for amyloid-β by positron emission tomography indicates that convergent pathologies, such as iron accumulation, might combine with amyloid-β to accelerate Alzheimer’s disease progression. Here, we applied quantitative susceptibility mapping, a relatively new magnetic resonance imaging method sensitive to tissue iron, to assess the relationship between iron, amyloid-β load, and cognitive decline in 117 subjects who underwent baseline magnetic resonance imaging and amyloid-β positron emission tomography from the Australian Imaging, Biomarkers and Lifestyle study (AIBL). Cognitive function data were collected every 18 months for up to 6 years from 100 volunteers who were either cognitively normal (n = 64) or diagnosed with mild cognitive impairment (n = 17) or Alzheimer’s disease (n = 19). Among participants with amyloid pathology (n = 45), higher hippocampal quantitative susceptibility mapping levels predicted accelerated deterioration in composite cognition tests for episodic memory [β(standard error) = −0.169 (0.034), P = 9.2 × 10−7], executive function [β(standard error) = −0.139 (0.048), P = 0.004), and attention [β(standard error) = −0.074 (0.029), P = 0.012]. Deteriorating performance in a composite of language tests was predicted by higher quantitative susceptibility mapping levels in temporal lobe [β(standard error) = −0.104 (0.05), P = 0.036] and frontal lobe [β(standard error) = −0.154 (0.055), P = 0.006]. These findings indicate that brain iron might combine with amyloid-β to accelerate clinical progression and that quantitative susceptibility mapping could be used in combination with amyloid-β positron emission tomography to stratify individuals at risk of decline.
  • W
    Walter
    Walter

    MicroCap Alert to PRAN shareholders. Why Clean Energy Technologies (CETY) shares moved up recently and why they are about to rise sharply again. CETY purchased their Heat Recovery Systems from General Electric.
    Each system sells for about $300,000. Demand for CETY HRS is very strong.
    CETY just expanded Europe sales and service office in high demand market
    CETY immediately announced first new sale in Europe
    CETY presenting to 26 Power Companies in the Pacific on July 31st to August 4th – These 26 power companies need CETY HRS to produce power cheaper and make more profits.

    Expect substantial sales orders to flow soon after conference
    CETY 1017 target: $.15 to $.20

    http://www.prnewswire.com/news-releases/clean-energy-technologies-inc-delivering-low-cost-emission-free-power-with-its-heat-recovery-solutions-clean-cycle-generator-acquired-from-general-electric-international-inc-300228398.html

    https://www.ppa.org.fj/26th-annual-ppa-conference/

    Clean Energy Technologies, Inc. Delivering Low Cost, Emission Free Power with its Heat Recovery Solutions Clean Cycle™ Generator acquired from General Electric International, Inc.
    COSTA MESA, Calif., March 1, 2016 /PRNewswire/ -- Clean Energy Technologies, Inc. (OTC: CETY), recently...
    www.prnewswire.com
  • F
    Frances
    Frances
    Release Date: 27/07/17 08:31
    Summary: Appendix 4C - quarterly
    Price Sensitive: Yes
    Download Document  697.27KB
  • K
    Kadaicher
    Kadaicher
    This is more like it. Takeda, market cap $40billion, now on board with PBT434 development. Been waiting for a Pharma to recognize the potential of Prana's MPACs for some time.
    From one year ago:
    [NEW YORK (TheStreet) -- Takeda Pharmaceutical (TKPYY) is looking for potential multi-billion dollar deals in the U.S. and other overseas markets as the Japanese pharmaceutical giant seeks to lower its dependence on sluggish domestic sales.

    Takeda CEO Christophe Weber would not confirm earlier reports that the company had set aside $10 billion to $15 billion for acquisitions, according to Reuters.
    Weber said the company is exploring more deals as Takeda has refocused several initiatives and is overhauling its research activities.]
    Looks like they just spotted the bargain of the decade. IMO
  • G
    Good Guy
    Good Guy
    Is PRAN selling at cash value? That's quite amazing given her potentials.
  • F
    Faith
    Faith
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on PRAN before rallying up. if you guys have questions you should ask awe*some*stock*s. They often respond to my emails which is helpful.
  • A
    Anonymous
    Anonymous

    KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • F
    Frances
    Frances
    ASX announcement today: Takeda Japan and Prana PD preclinical PBT434 investigative collaboration. Appears that they will study Parkinson's gastro-intestinal neuropathology and continue plan for Phase I later this year. No description of part each company will play in the collaboration which was reported by Prana, no input yet from Takeda.

    Release Date: 18/07/17 10:04
    Summary: Prana commences research collaboration with Takeda
    Price Sensitive: Yes
    Download Document  618.4KB.
  • L
    Lauren
    Lauren
    The scenarios are quite interesting at current levels for PRAN. I started receiving notifications from awe-SOME-stock-s the other week and so far they have presented interesting new trade ideas.
  • F
    Frances
    Frances
    It's questionable if anyone is alive and well at Prana headquarters. A vague "price sensitive" announcement about an investigative collaborative research deal with Takeda, a Japanese international corporation, contained few details. A few posters were ecstatic but there was no actual follow-up, especially no input from Takeda about what they could do for PBT434 in preclinical stage.
  • B
    Bob
    Bob
    Does anyone wonder why Frances (aka Copper, xrx2 on hotcopper who got banned) keeps stalking PRAN and PBT? Textbook definition of a STALKER. Get a life you Loser!
  • F
    Frances
    Frances
    Prana seems to be comfortable remaining in the $2.70's range.....bid $2.73 x 100, ask $2.77 x 1,900.
    PBT appears to be content with a nickel to six cents range. Volume stays low as per usual daily.

    Any collaborative partners in sight?